Addex Therapeutics Ltd - Product Pipeline Review - 2016

Published: May, 2016 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Addex Therapeutics Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Addex Therapeutics Ltd - Product Pipeline Review - 2016', provides an overview of the Addex Therapeutics Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Addex Therapeutics Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Addex Therapeutics Ltd
- The report provides overview of Addex Therapeutics Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Addex Therapeutics Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Addex Therapeutics Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Addex Therapeutics Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Addex Therapeutics Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Addex Therapeutics Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Addex Therapeutics Ltd Snapshot 6
Addex Therapeutics Ltd Overview 6
Key Information 6
Key Facts 6
Addex Therapeutics Ltd - Research and Development Overview 7
Key Therapeutic Areas 7
Addex Therapeutics Ltd - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Addex Therapeutics Ltd - Pipeline Products Glance 15
Addex Therapeutics Ltd - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Addex Therapeutics Ltd - Early Stage Pipeline Products 17
IND/CTA Filed Products/Combination Treatment Modalities 17
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Addex Therapeutics Ltd - Drug Profiles 20
dipraglurant IR 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
dipraglurant ER 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ADX-71441 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ADX-71743 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ADX-88178 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ADX-92639 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule to Inhibit FSHR/LHR For Sex Hormone Dependent Tumors 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ADX-90125 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ADX-95477 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule to Antagonize FSH Receptor for Women's Health 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules to Agonize TRKB for Alzheimer's Disease 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Modulate mGlu3 Receptor for CNS Disorders 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Addex Therapeutics Ltd - Pipeline Analysis 39
Addex Therapeutics Ltd - Pipeline Products by Target 39
Addex Therapeutics Ltd - Pipeline Products by Route of Administration 41
Addex Therapeutics Ltd - Pipeline Products by Molecule Type 42
Addex Therapeutics Ltd - Pipeline Products by Mechanism of Action 43
Addex Therapeutics Ltd - Recent Pipeline Updates 44
Addex Therapeutics Ltd - Dormant Projects 51
Addex Therapeutics Ltd - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
ADX-10059 52
ADX-10061 52
ADX-71943 52
Addex Therapeutics Ltd - Company Statement 53
Addex Therapeutics Ltd - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Addex Therapeutics Ltd, Key Information 6
Addex Therapeutics Ltd, Key Facts 6
Addex Therapeutics Ltd - Pipeline by Indication, 2016 8
Addex Therapeutics Ltd - Pipeline by Stage of Development, 2016 11
Addex Therapeutics Ltd - Monotherapy Products in Pipeline, 2016 12
Addex Therapeutics Ltd - Out-Licensed Products in Pipeline, 2016 13
Addex Therapeutics Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
Addex Therapeutics Ltd - Phase II, 2016 15
Addex Therapeutics Ltd - Phase I, 2016 16
Addex Therapeutics Ltd - IND/CTA Filed, 2016 17
Addex Therapeutics Ltd - Preclinical, 2016 18
Addex Therapeutics Ltd - Discovery, 2016 19
Addex Therapeutics Ltd - Pipeline by Target, 2016 40
Addex Therapeutics Ltd - Pipeline by Route of Administration, 2016 41
Addex Therapeutics Ltd - Pipeline by Molecule Type, 2016 42
Addex Therapeutics Ltd - Pipeline Products by Mechanism of Action, 2016 43
Addex Therapeutics Ltd - Recent Pipeline Updates, 2016 44
Addex Therapeutics Ltd - Dormant Developmental Projects,2016 51
Addex Therapeutics Ltd - Discontinued Pipeline Products, 2016 52
Addex Therapeutics Ltd, Subsidiaries 55